Pivotal NGN-401 trial speeds toward dosing for people with Rett
Neurogene expects dosing for a registrational clinical trial of its investigational gene therapy NGN-401 for people with Rett syndrome will start by the end 2025. The U.S. Food and Drug Administration (FDA) agreed to key elements of the trial design over the summer, and Neurogene reports it…